U.S. markets open in 4 hours 31 minutes
  • S&P Futures

    4,172.75
    +15.00 (+0.36%)
     
  • Dow Futures

    34,346.00
    +90.00 (+0.26%)
     
  • Nasdaq Futures

    13,408.25
    +104.75 (+0.79%)
     
  • Russell 2000 Futures

    2,234.30
    +8.80 (+0.40%)
     
  • Crude Oil

    66.70
    +0.43 (+0.65%)
     
  • Gold

    1,869.90
    +2.30 (+0.12%)
     
  • Silver

    28.67
    +0.39 (+1.38%)
     
  • EUR/USD

    1.2222
    +0.0065 (+0.54%)
     
  • 10-Yr Bond

    1.6400
    0.0000 (0.00%)
     
  • Vix

    19.23
    +0.42 (+2.23%)
     
  • GBP/USD

    1.4210
    +0.0073 (+0.51%)
     
  • USD/JPY

    108.8600
    -0.3400 (-0.31%)
     
  • BTC-USD

    45,138.89
    -212.42 (-0.47%)
     
  • CMC Crypto 200

    1,256.35
    +58.44 (+4.88%)
     
  • FTSE 100

    7,062.05
    +29.20 (+0.42%)
     
  • Nikkei 225

    28,406.84
    +582.01 (+2.09%)
     

UPDATE 1-EU drug regulator to issue view on J&J vaccine next week

  • Oops!
    Something went wrong.
    Please try again later.
  • Oops!
    Something went wrong.
    Please try again later.
·1 min read
  • Oops!
    Something went wrong.
    Please try again later.
  • Oops!
    Something went wrong.
    Please try again later.

* EMA expects to issue recommendation following review

* U.S. paused J&J vaccine use to look into rare clotting

* EMA says benefits of J&J vaccine still outweigh risks

* J&J has recommended EU countries suspend use of its vaccine (Adds background)

April 14 (Reuters) - Europe's drug regulator said on Wednesday it planned to issue a recommendation on Johnson & Johnson's COVID-19 vaccine next week, but that it continued to believe the benefits of the shot outweighed the risks of side effects.

The European Medicines Agency (EMA) is reviewing a small number of cases in the United States of very rare blood clotting disorders among people who had received the J&J vaccine.

The agency also said J&J had recommended EU member states hold on to the doses they had already received until the watchdog's safety committee issues its recommendation.

J&J said on Tuesday it would "proactively delay" the rollout of its vaccine in Europe, after U.S. federal health agencies recommended pausing its use for at least a few days after six women under the age of 50 developed rare blood clots after receiving the shot.

The vaccine was authorised in the European Union on March 11 but widespread use in the bloc has not yet started, trailing a rollout in the United States.

Investigations into rare blood clots linked to AstraZeneca's shot have already hobbled Europe's vaccine rollout. Denmark said on Wednesday it would drop AstraZeneca's vaccine, which is similar to J&J's, over the risk. (Reporting by Yadarisa Shabong in Bengaluru, Ludwig Burger in Frankfurt; Editing by Aditya Soni and Mark Potter)